HRP20110360T1 - Kombinacija zd6474 i pemetrekseda - Google Patents
Kombinacija zd6474 i pemetrekseda Download PDFInfo
- Publication number
- HRP20110360T1 HRP20110360T1 HR20110360T HRP20110360T HRP20110360T1 HR P20110360 T1 HRP20110360 T1 HR P20110360T1 HR 20110360 T HR20110360 T HR 20110360T HR P20110360 T HRP20110360 T HR P20110360T HR P20110360 T1 HRP20110360 T1 HR P20110360T1
- Authority
- HR
- Croatia
- Prior art keywords
- pemetrexed
- human
- warm
- blooded animal
- pharmaceutically acceptable
- Prior art date
Links
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 title claims abstract 10
- 229960005079 pemetrexed Drugs 0.000 title claims abstract 10
- 241001465754 Metazoa Species 0.000 claims abstract 7
- 206010028980 Neoplasm Diseases 0.000 claims abstract 5
- 238000004519 manufacturing process Methods 0.000 claims abstract 5
- 201000011510 cancer Diseases 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 230000005865 ionizing radiation Effects 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000037841 lung tumor Diseases 0.000 claims 2
- 208000006178 malignant mesothelioma Diseases 0.000 claims 2
- 201000005282 malignant pleural mesothelioma Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 230000001093 anti-cancer Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract 3
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 2
- 230000005855 radiation Effects 0.000 abstract 2
- 230000001603 reducing effect Effects 0.000 abstract 2
- 230000008728 vascular permeability Effects 0.000 abstract 2
- 239000013066 combination product Substances 0.000 abstract 1
- 229940127555 combination product Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
Upotreba ZD6474 ili njegove farmaceutski prihvatljive soli i pemetrekseda, naznačena time da je za proizvodnju lijeka za upotrebu kod postizanja anti-kancerogenog učinka kod toplokrvne životinje kao što je čovjek. Patent sadrži još 7 patentnih zahtjeva.
Claims (8)
1. Upotreba ZD6474 ili njegove farmaceutski prihvatljive soli i pemetrekseda, naznačena time da je za proizvodnju lijeka za upotrebu kod postizanja anti-kancerogenog učinka kod toplokrvne životinje kao što je čovjek.
2. Upotreba ZD6474 ili njegove farmaceutski prihvatljive soli i pemetrekseda, naznačena time da je za proizvodnju lijeka za upotrebu kod postizanja anti-tumorskog učinka kod toplokrvne životinje kao što je čovjek.
3. Upotreba prema zahtjevu 1 naznačena time da toplokrvna životinja kao što je čovjek je tretirana sa ionizirajućim zračenjem.
4. Upotreba prema zahtjevu 2 naznačena time da toplokrvna životinja kao što je čovjek je tretirana sa ionizirajućim zračenjem.
5. Upotreba prema zahtjevu 2 ili zahtjevu 4 naznačena time da tumor je maligni pleuralni mezoteliom ili je tumor pluća nemalih stanica ili je tumor pluća malih stanica.
6. Upotreba prema zahtjevu 1 ili zahtjevu 3 naznačena time da rak je karcinom pluća nemalih stanica (NSCLC) ili maligni pleuralni mezoteliom ili karcinom pluća malih stanica (SCLC).
7. Farmaceutski pripravak naznačen time da sadrži ZD6474 ili njegovu farmaceutski prihvatljivu sol, i pemetreksed u kombinaciji sa farmaceutski prihvatljivom pomoćnom tvari ili nosačem.
8. Kit naznačen time da sadrži ZD6474 ili njegovu farmaceutski prihvatljivu sol, i pemetreksed.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0526121A GB0526121D0 (en) | 2005-12-22 | 2005-12-22 | Combination therapy |
| GB0610706A GB0610706D0 (en) | 2006-05-31 | 2006-05-31 | Combination therapy |
| PCT/GB2006/004750 WO2007071958A2 (en) | 2005-12-22 | 2006-12-19 | Combination of zd6474 and pemetrexed |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110360T1 true HRP20110360T1 (hr) | 2011-06-30 |
Family
ID=37814151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110360T HRP20110360T1 (hr) | 2005-12-22 | 2011-05-16 | Kombinacija zd6474 i pemetrekseda |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20080269261A1 (hr) |
| EP (1) | EP1971338B8 (hr) |
| JP (1) | JP5167144B2 (hr) |
| KR (1) | KR20080079675A (hr) |
| AT (1) | ATE500832T1 (hr) |
| AU (1) | AU2006328189B2 (hr) |
| BR (1) | BRPI0620140A2 (hr) |
| CA (1) | CA2631764A1 (hr) |
| CY (1) | CY1111547T1 (hr) |
| DE (1) | DE602006020621D1 (hr) |
| DK (1) | DK1971338T3 (hr) |
| HK (1) | HK1123186A1 (hr) |
| HR (1) | HRP20110360T1 (hr) |
| IL (1) | IL191796A0 (hr) |
| NO (1) | NO20082567L (hr) |
| NZ (1) | NZ568811A (hr) |
| PL (1) | PL1971338T3 (hr) |
| PT (1) | PT1971338E (hr) |
| SI (1) | SI1971338T1 (hr) |
| WO (1) | WO2007071958A2 (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| PT1592423E (pt) * | 2003-02-13 | 2011-06-16 | Astrazeneca Ab | Terapia de combinação de zd6474 com 5-fu e/ou cpt-11 |
| CA2531862C (en) * | 2003-07-10 | 2011-10-25 | Astrazenca Ab | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| GB0318422D0 (en) * | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| JP2008514577A (ja) * | 2004-09-27 | 2008-05-08 | アストラゼネカ アクチボラグ | Ｚｄ６４７４及びイマチニブを含んでなる組合せ |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| SI1971338T1 (sl) * | 2005-12-22 | 2011-06-30 | Astrazeneca Ab | Kombinacija ZD6474 in pemetrekseda |
| WO2007071970A2 (en) * | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Combination of azd2171 and pemetrexed |
| EP2066353B1 (en) * | 2006-09-29 | 2013-01-02 | AstraZeneca AB | Combination of zd6474 and bevacizumab for cancer therapy |
| US20090221615A1 (en) * | 2008-02-29 | 2009-09-03 | Guru Reddy | Combination anti-cancer agents |
| ES2727273T3 (es) | 2010-03-08 | 2019-10-15 | Spectrum Pharmaceuticals Inc | Terapias inhibidoras de la autofagia basadas en tioxantina para tratar el cáncer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1014953B1 (en) * | 1997-03-05 | 2012-04-25 | Sugen, Inc. | Formulations for hydrophobic pharmaceutical agents |
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| US7001911B2 (en) * | 2000-06-28 | 2006-02-21 | Bristol-Myers Squibb Company | Fused cyclic modulators of nuclear hormone receptor function |
| CA2417495C (en) * | 2000-07-28 | 2013-04-30 | Sloan-Kettering Institute For Cancer Research | Methods for treating cell proliferative disorders and viral infections |
| GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| CA2495487A1 (en) * | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| PT1592423E (pt) * | 2003-02-13 | 2011-06-16 | Astrazeneca Ab | Terapia de combinação de zd6474 com 5-fu e/ou cpt-11 |
| CA2531862C (en) * | 2003-07-10 | 2011-10-25 | Astrazenca Ab | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| JP2008514577A (ja) * | 2004-09-27 | 2008-05-08 | アストラゼネカ アクチボラグ | Ｚｄ６４７４及びイマチニブを含んでなる組合せ |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| SI1971338T1 (sl) * | 2005-12-22 | 2011-06-30 | Astrazeneca Ab | Kombinacija ZD6474 in pemetrekseda |
| WO2007071970A2 (en) * | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Combination of azd2171 and pemetrexed |
| EP2066353B1 (en) * | 2006-09-29 | 2013-01-02 | AstraZeneca AB | Combination of zd6474 and bevacizumab for cancer therapy |
-
2006
- 2006-12-19 SI SI200630997T patent/SI1971338T1/sl unknown
- 2006-12-19 WO PCT/GB2006/004750 patent/WO2007071958A2/en active Application Filing
- 2006-12-19 DK DK06820566.5T patent/DK1971338T3/da active
- 2006-12-19 DE DE602006020621T patent/DE602006020621D1/de active Active
- 2006-12-19 PL PL06820566T patent/PL1971338T3/pl unknown
- 2006-12-19 US US12/158,264 patent/US20080269261A1/en not_active Abandoned
- 2006-12-19 CA CA002631764A patent/CA2631764A1/en not_active Abandoned
- 2006-12-19 BR BRPI0620140-7A patent/BRPI0620140A2/pt not_active Application Discontinuation
- 2006-12-19 AU AU2006328189A patent/AU2006328189B2/en not_active Ceased
- 2006-12-19 PT PT06820566T patent/PT1971338E/pt unknown
- 2006-12-19 KR KR1020087016946A patent/KR20080079675A/ko not_active Application Discontinuation
- 2006-12-19 AT AT06820566T patent/ATE500832T1/de active
- 2006-12-19 NZ NZ568811A patent/NZ568811A/en not_active IP Right Cessation
- 2006-12-19 EP EP06820566A patent/EP1971338B8/en active Active
- 2006-12-19 JP JP2008546586A patent/JP5167144B2/ja not_active Expired - Fee Related
-
2008
- 2008-05-28 IL IL191796A patent/IL191796A0/en unknown
- 2008-06-02 NO NO20082567A patent/NO20082567L/no not_active Application Discontinuation
-
2009
- 2009-01-14 HK HK09100369.4A patent/HK1123186A1/xx not_active IP Right Cessation
-
2010
- 2010-09-28 US US12/892,478 patent/US20110212978A1/en not_active Abandoned
-
2011
- 2011-05-16 HR HR20110360T patent/HRP20110360T1/hr unknown
- 2011-06-08 CY CY20111100546T patent/CY1111547T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL191796A0 (en) | 2008-12-29 |
| JP5167144B2 (ja) | 2013-03-21 |
| CY1111547T1 (el) | 2015-08-05 |
| US20080269261A1 (en) | 2008-10-30 |
| PT1971338E (pt) | 2011-05-09 |
| DE602006020621D1 (de) | 2011-04-21 |
| NO20082567L (no) | 2008-07-31 |
| AU2006328189A1 (en) | 2007-06-28 |
| EP1971338B8 (en) | 2011-09-21 |
| WO2007071958A3 (en) | 2008-03-27 |
| KR20080079675A (ko) | 2008-09-01 |
| JP2009520783A (ja) | 2009-05-28 |
| PL1971338T3 (pl) | 2011-07-29 |
| AU2006328189B2 (en) | 2010-01-21 |
| CA2631764A1 (en) | 2007-06-28 |
| BRPI0620140A2 (pt) | 2011-11-01 |
| SI1971338T1 (sl) | 2011-06-30 |
| WO2007071958A2 (en) | 2007-06-28 |
| DK1971338T3 (da) | 2011-05-23 |
| ATE500832T1 (de) | 2011-03-15 |
| HK1123186A1 (en) | 2009-06-12 |
| EP1971338A2 (en) | 2008-09-24 |
| EP1971338B1 (en) | 2011-03-09 |
| US20110212978A1 (en) | 2011-09-01 |
| NZ568811A (en) | 2011-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110360T1 (hr) | Kombinacija zd6474 i pemetrekseda | |
| HRP20110365T1 (hr) | Kombinacija azd2171 i pemetrekseda | |
| HK1078771A1 (en) | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer | |
| MX2007003506A (es) | Terapia de combinacion de cancer que comprende azd2171 e imatinib. | |
| MX2007003505A (es) | Combinacion que comprende zd6474 e imatinib. | |
| JP2006500346A5 (hr) | ||
| HRP20080597T3 (hr) | Kombinirana terapija raka koja obuhvaća azd2171 izd1839 | |
| HK1096023A1 (en) | Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11 | |
| MXPA05008583A (es) | Terapia de combinacion de zd6474 con 5-fu y/o cpt-11. | |
| WO2007003933A3 (en) | Combination therapy of cancer with azd2171 and gemcitabine | |
| MXPA05013827A (es) | Composiciones que comprenden zd6126 junto con 5-fu, cpt-11 o 5-fu y cpt-11, que tienen actividad de dano vascular, para tratar cancer colorectal e. g. | |
| BR0315087A (pt) | Métodos para a produção de um efeito de dano vascular em um animal de sangue quente e para o tratamento de câncer envolvendo um tumor sólido em um animal de sangue quente, composição farmacêutica, kit, e, uso de zd6126 ou um sal deste farmaceuticamente aceitável e gencitabina |